IS7058A - Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3-[4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxýprópansýru og bígúaníðlyf - Google Patents
Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3-[4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxýprópansýru og bígúaníðlyfInfo
- Publication number
- IS7058A IS7058A IS7058A IS7058A IS7058A IS 7058 A IS7058 A IS 7058A IS 7058 A IS7058 A IS 7058A IS 7058 A IS7058 A IS 7058A IS 7058 A IS7058 A IS 7058A
- Authority
- IS
- Iceland
- Prior art keywords
- ethoxy
- phenyl
- butoxycarbonylaminophenyl
- tert
- methanesulfonylloxyphenyl
- Prior art date
Links
- QNDFBOXBUCDYNZ-NRFANRHFSA-N (2s)-2-ethoxy-3-[4-[2-[4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]ethoxy]phenyl]propanoic acid Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(NC(=O)OC(C)(C)C)C=C1 QNDFBOXBUCDYNZ-NRFANRHFSA-N 0.000 title abstract 2
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 title abstract 2
- 229940123208 Biguanide Drugs 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 title 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
- 235000019260 propionic acid Nutrition 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- CXGTZJYQWSUFET-IBGZPJMESA-N tesaglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 CXGTZJYQWSUFET-IBGZPJMESA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0101980A SE0101980D0 (sv) | 2001-06-01 | 2001-06-01 | Pharmaceutical combination |
PCT/SE2002/001038 WO2002096402A1 (en) | 2001-06-01 | 2002-05-30 | A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a biguanide drug |
Publications (1)
Publication Number | Publication Date |
---|---|
IS7058A true IS7058A (is) | 2003-11-28 |
Family
ID=20284362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS7058A IS7058A (is) | 2001-06-01 | 2003-11-28 | Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3-[4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxýprópansýru og bígúaníðlyf |
Country Status (25)
Country | Link |
---|---|
US (1) | US20040152771A1 (is) |
EP (2) | EP1666034A1 (is) |
JP (1) | JP2004532864A (is) |
KR (1) | KR20040008202A (is) |
CN (1) | CN1535144A (is) |
AT (1) | ATE336993T1 (is) |
BR (1) | BR0210128A (is) |
CA (1) | CA2448643A1 (is) |
CO (1) | CO5540375A2 (is) |
CZ (1) | CZ20033234A3 (is) |
DE (1) | DE60214185T2 (is) |
EE (1) | EE200300584A (is) |
ES (1) | ES2269686T3 (is) |
HK (1) | HK1062813A1 (is) |
HU (1) | HUP0400946A3 (is) |
IL (1) | IL159033A0 (is) |
IS (1) | IS7058A (is) |
MX (1) | MXPA03011005A (is) |
NO (1) | NO20035237D0 (is) |
PL (1) | PL367891A1 (is) |
RU (1) | RU2003136154A (is) |
SE (1) | SE0101980D0 (is) |
SK (1) | SK14702003A3 (is) |
WO (1) | WO2002096402A1 (is) |
ZA (1) | ZA200309264B (is) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201513857A (zh) * | 2013-07-05 | 2015-04-16 | Cadila Healthcare Ltd | 協同性組成物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5783556A (en) * | 1996-08-13 | 1998-07-21 | Genentech, Inc. | Formulated insulin-containing composition |
US6552055B2 (en) * | 1996-12-11 | 2003-04-22 | Dana-Farber Cancer Institute | Methods and pharmaceutical compositions for inhibiting tumor cell growth |
US6011049A (en) * | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
SE9801990D0 (sv) * | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl propionic acid derivatives and analogs |
SE9801992D0 (sv) * | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
DK1145717T3 (da) * | 2000-04-13 | 2004-08-02 | Pfizer Prod Inc | Synergistisk virkning af glyburid og milrinon |
-
2001
- 2001-06-01 SE SE0101980A patent/SE0101980D0/xx unknown
-
2002
- 2002-05-30 IL IL15903302A patent/IL159033A0/xx unknown
- 2002-05-30 CA CA002448643A patent/CA2448643A1/en not_active Abandoned
- 2002-05-30 RU RU2003136154/15A patent/RU2003136154A/ru not_active Application Discontinuation
- 2002-05-30 JP JP2002592913A patent/JP2004532864A/ja not_active Withdrawn
- 2002-05-30 HU HU0400946A patent/HUP0400946A3/hu unknown
- 2002-05-30 EE EEP200300584A patent/EE200300584A/xx unknown
- 2002-05-30 KR KR10-2003-7015601A patent/KR20040008202A/ko not_active Application Discontinuation
- 2002-05-30 CZ CZ20033234A patent/CZ20033234A3/cs unknown
- 2002-05-30 EP EP06000170A patent/EP1666034A1/en not_active Withdrawn
- 2002-05-30 ES ES02728300T patent/ES2269686T3/es not_active Expired - Lifetime
- 2002-05-30 MX MXPA03011005A patent/MXPA03011005A/es unknown
- 2002-05-30 DE DE60214185T patent/DE60214185T2/de not_active Expired - Fee Related
- 2002-05-30 EP EP02728300A patent/EP1404309B1/en not_active Expired - Lifetime
- 2002-05-30 SK SK1470-2003A patent/SK14702003A3/sk not_active Application Discontinuation
- 2002-05-30 CN CNA028149394A patent/CN1535144A/zh active Pending
- 2002-05-30 PL PL02367891A patent/PL367891A1/xx not_active Application Discontinuation
- 2002-05-30 US US10/478,798 patent/US20040152771A1/en not_active Abandoned
- 2002-05-30 WO PCT/SE2002/001038 patent/WO2002096402A1/en not_active Application Discontinuation
- 2002-05-30 BR BR0210128-9A patent/BR0210128A/pt not_active IP Right Cessation
- 2002-05-30 AT AT02728300T patent/ATE336993T1/de not_active IP Right Cessation
-
2003
- 2003-11-25 NO NO20035237A patent/NO20035237D0/no not_active Application Discontinuation
- 2003-11-27 ZA ZA200309264A patent/ZA200309264B/en unknown
- 2003-11-28 IS IS7058A patent/IS7058A/is unknown
- 2003-12-23 CO CO03112108A patent/CO5540375A2/es not_active Application Discontinuation
-
2004
- 2004-08-02 HK HK04105673A patent/HK1062813A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
BR0210128A (pt) | 2004-06-08 |
ATE336993T1 (de) | 2006-09-15 |
SE0101980D0 (sv) | 2001-06-01 |
JP2004532864A (ja) | 2004-10-28 |
HK1062813A1 (en) | 2004-11-26 |
MXPA03011005A (es) | 2004-02-27 |
WO2002096402A1 (en) | 2002-12-05 |
EE200300584A (et) | 2004-02-16 |
SK14702003A3 (sk) | 2004-09-08 |
NO20035237D0 (no) | 2003-11-25 |
ZA200309264B (en) | 2005-02-28 |
CZ20033234A3 (cs) | 2004-12-15 |
DE60214185D1 (en) | 2006-10-05 |
EP1404309A1 (en) | 2004-04-07 |
IL159033A0 (en) | 2004-05-12 |
CN1535144A (zh) | 2004-10-06 |
EP1666034A1 (en) | 2006-06-07 |
KR20040008202A (ko) | 2004-01-28 |
DE60214185T2 (de) | 2007-07-19 |
CO5540375A2 (es) | 2005-07-29 |
RU2003136154A (ru) | 2005-02-10 |
HUP0400946A3 (en) | 2007-11-28 |
US20040152771A1 (en) | 2004-08-05 |
HUP0400946A2 (hu) | 2004-08-30 |
PL367891A1 (en) | 2005-03-07 |
ES2269686T3 (es) | 2007-04-01 |
CA2448643A1 (en) | 2002-12-05 |
EP1404309B1 (en) | 2006-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1090294A1 (en) | Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4- oxadiazol-2-yl] phenyl)pyridine-3-sulphonamide and a biphosphonate ; | |
BR9910913A (pt) | Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, e, processo para a profilaxia e/ou tratamento de condições clìnicas associadas com resistência a insulina | |
NO20022591D0 (no) | Finmalt form av (S)-2-etoksy-3-[4-(2-{4- metansulfonyloksyfenyl}etoksy)fenyl]propansyre | |
BR0207509A (pt) | Pirazolilpirimidinas | |
IS7058A (is) | Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3-[4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxýprópansýru og bígúaníðlyf | |
PE20070612A1 (es) | Nuevos inhibidores de cisteina proteasas | |
IL172633A0 (en) | Amine salts of (-)-2-{[2-(4-hydroxyphenyl) ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy} | |
SE0101982D0 (sv) | Pharmaceutical combination | |
SE0101981D0 (sv) | Pharmaceutical combination | |
IS8234A (is) | Kalíum- eða natríumsalt (-)-2-{[2-(4-hýdroxýfenýl)etýl]þíó}-3-[4-(2-{4-[(metýlsúlfónýl)oxý]fenoxý}fenýl]própansýru og notkun þeirra í læknisfræði | |
HUP0303027A2 (hu) | Új benzoil-guanidin só és alkalmazása gyógyszerkészítmény előállítására | |
PE20090807A1 (es) | Sulfonamidas substituidas, proceso para su preparacion y composicion farmaceutica de las mismas | |
ATE348605T1 (de) | Stabilisierte formulierungen von 6-hydroxy-3-(4- (2-(piperidin-1-yl)ethoxy)phenoxy)-2-(4- methoxyphenyl)benzo(b)thiophen und deren salze | |
DE60310896D1 (de) | PHARMAZEUTISCHE ZUBEREITUNGEN ENTHALTEND NANOPARTIKEL VON 2-(4-ETHOXY-PHENYL)-3-(4-METHANSULPHONYL-PHENYL)-PYRAZOLOi1,5-BöPYRIDAZIN | |
AU2002254631A1 (en) | Enantiomers of n-((2'-(((4,5-dimethyl-3-isoxazolyl) amino)sulfonyl)-4-(2-oxazolyl)(1,1'-biphenyl)-2-yl)methyl)-n,3,3-trimethylbutanamide | |
AR038306A1 (es) | Composicion farmaceutica dispersable oralmente de 2-({2-metoxi-2-[(3-trifluorometil)fenil]etil}amino)etil-4-(2-{[2-(9h-fluoren-9-il)acetil]amino}etil)benzoato | |
DE60142063D1 (de) | (2s)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propion säureisopropylester, dessen herstellung und dessen verwendung |